Belite Bio Inc
NASDAQ:BLTE
Belite Bio Inc
NASDAQ:BLTE
Price:
152.62
USD
-0.07%
Market Closed
Market Cap:
$6.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Belite Bio Inc
NASDAQ:BLTE
|
US |
|
S
|
Shape Robotics A/S
CSE:SHAPE
|
DK |
|
N
|
Nusa Konstruksi Enjiniring Tbk PT
IDX:DGIK
|
ID |
|
G
|
George Weston Ltd
OTC:WNGRF
|
CA |
|
D
|
Diamondback Energy Inc
F:7DB
|
US |
|
PayPal Holdings Inc
BMV:PYPL
|
US |
|
V
|
Vintcom Technology PCL
SET:VCOM
|
TH |
|
T
|
Thai Eastern Group Holdings PCL
SET:TEGH
|
TH |
|
Swiss Re AG
SIX:SREN
|
CH |
|
Tamburi Investment Partners SpA
MIL:TIP
|
IT |
|
Scanfil Oyj
F:S0A
|
FI |
|
S
|
Siav SpA
F:F4U
|
IT |
|
Cresud SACIF y A
NASDAQ:CRESY
|
AR |
|
C
|
Clearmind Medicine Inc
NASDAQ:CMND
|
CA |
|
Brunswick Corp
NYSE:BC
|
US |
|
Pattern SpA
MIL:PTR
|
IT |
|
Super Energy Tbk PT
IDX:SURE
|
ID |
|
Adavale Resources Ltd
ASX:ADD
|
AU |
|
C
|
Cheryong Electric Co Ltd
KOSDAQ:033100
|
KR |
|
Toyota Motor Corp
F:TOM
|
JP |
|
F
|
Fillamentum as
PSE:FILL
|
CZ |
Intrinsic Value
Not Available for BLTE
There is not enough data to reliably calculate the intrinsic value for Belite Bio Inc.
Do our valuations actually work? See backtest results .
Alternatives to BLTE
Fundamental Analysis
What Belite Bio Does
Belite Bio is a clinical-stage drug developer focused on eye diseases that damage the retina and can lead to vision loss. Its main work is developing oral medicines for conditions such as Stargardt disease and dry age-related macular degeneration, where patients need long-term treatment to slow or prevent further damage.
- Headquarters
- United States of America US
- Employees
- 41
- IPO date
- Apr 29, 2022
Financials
Efficiency
Earnings Waterfall
Belite Bio Inc
Belite Bio Inc
